Identifying the Role of Symptom Outcomes and Biomarkers in Survival in Patients With Metastatic Pancreatic Cancer
A Feasibility Study for Identifying the Role of Symptom Outcomes and Biomarkers in Survival in Patients With Metastatic Pancreatic Cancer
Sponsor: M.D. Anderson Cancer Center
Listed as NCT00805688, this observational or N/A phase trial focuses on Pancreatic Cancer and remains completed. Sponsored by M.D. Anderson Cancer Center, it has been updated 12 times since 2008, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2021 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
-
Nov 2020 — Jan 2021 [monthly]
Completed
▶ Show 7 earlier versions
-
Jun 2018 — Nov 2020 [monthly]
Completed
-
May 2018 — Jun 2018 [monthly]
Completed
-
Apr 2018 — May 2018 [monthly]
Completed
Phase: NA → None
-
Mar 2018 — Apr 2018 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Feb 2018 — Mar 2018 [monthly]
Active Not Recruiting NA
-
Aug 2017 — Feb 2018 [monthly]
Active Not Recruiting NA
-
Jan 2017 — Aug 2017 [monthly]
Active Not Recruiting NA
First recorded
Nov 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- M.D. Anderson Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .